
Leaders in hepatitis screening
Timely diagnosis stops spread of disease and facilitates linkage to care

99.7% Sensitivity
(Sanquin Blood Supply Foundation, International Red Cross, The Netherlands)
99.8% Specificity
(German Red Cross Baden-Württemberg-Hesseng GmbH)

Seroconversion panels used in device evaluation requirements

Reading time

Reliable quality

Responsible pricing

Equal performance with whole blood and in finger stick blood testing

Proven optimum performance in the field studies

Suitable for near patient testing
Experts in HCV near patient screening
130-150
million people worldwide have chronic Hep C
160,000
cases of acute Hep C were reported in the U.S. in 2009
Central & East Asia and North Africa have the highest Hep C rates

HCV treatment landscape
Over the past few years, the introduction of direct acting antivirals has revolutionized treatment for Hepatitis C. With short durations, minimum side effects, and over 90% cure rates, campaign for HCV eradication such as No Hep campaign has gradually risen as a top priority on public health agendas as experts have begun to recognize the impact of test and treat initiatives on reducing future healthcare burden.
While these new medications are an exciting improvement, at present, only a small percentage of people know their status, and access to affordable and user-friendly tests is vital to the success of these test and treat initiatives.
While these new medications are an exciting improvement, at present, only a small percentage of people know their status, and access to affordable and user-friendly tests is vital to the success of these test and treat initiatives.
FOUNDATION OF ACCURATE HCV TESTING
Provision of reliable, high quality, regulatory approved test kits
Qualified, trained and supported testing personnel
Quality-assured testing environments that address quality control, equipment management, accurate record-keeping and external quality assessment (EQA) schemes
Our responsibility
As we recognize the need for manufacturers to support this public health agenda, InTec Products has taken great lengths to optimize its testing platform with refined bioactive materials and state-of-the-art manufacturing facilities to ensure that high quality tests can be implemented in the field.
To meet the requirements of genotype variability and sub-optimal storage conditions, we have gone through great lengths to assure the quality of our tests with internal validations and external qualifications that testify to the performance of our tests.
With over 300 million sold over the past 20 years, we believe we carry the proper experience to meet the demands for quality and consistent supply that are required for manufacturers to responsibly impact the initiative against Hepatitis C.
To meet the requirements of genotype variability and sub-optimal storage conditions, we have gone through great lengths to assure the quality of our tests with internal validations and external qualifications that testify to the performance of our tests.
With over 300 million sold over the past 20 years, we believe we carry the proper experience to meet the demands for quality and consistent supply that are required for manufacturers to responsibly impact the initiative against Hepatitis C.
About NoHep Campaign and 2030 HCV Elimination Goals

HCV Care continuum stages
HCV CARE CONTINUUM ARE SERIES OF STEPS FROM INITIAL CASE FINDING / DIAGNOSIS TO ULTIMATE SVR / CURE
